NASDAQ:TLSA - Nasdaq - BMG889121031 - Common Stock - Currency: USD
1.6
-0.05 (-3.03%)
The current stock price of TLSA is 1.6 USD. In the past month the price increased by 6.67%. In the past year, price increased by 100%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.06 | 327.65B | ||
AMGN | AMGEN INC | 13.95 | 155.74B | ||
GILD | GILEAD SCIENCES INC | 13.95 | 134.34B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 115.15B | ||
REGN | REGENERON PHARMACEUTICALS | 11.59 | 55.45B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.72B | ||
ARGX | ARGENX SE - ADR | 93.55 | 32.85B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.47 | 27.35B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.10B | ||
NTRA | NATERA INC | N/A | 23.35B | ||
BIIB | BIOGEN INC | 8 | 18.54B | ||
INSM | INSMED INC | N/A | 18.12B |
Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in developing therapies for neurodegenerative and lung diseases. The Company’s clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Alzheimer’s, and ALS. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine.
TIZIANA LIFE SCIENCES LTD
3rd Floor, 11-12 St. James's Square
London SW1Y 4LB GB
CEO: Kunwar Shailubhai
Employees: 9
Phone: 442074952379
The current stock price of TLSA is 1.6 USD. The price decreased by -3.03% in the last trading session.
The exchange symbol of TIZIANA LIFE SCIENCES LTD is TLSA and it is listed on the Nasdaq exchange.
TLSA stock is listed on the Nasdaq exchange.
TIZIANA LIFE SCIENCES LTD (TLSA) has a market capitalization of 178.34M USD. This makes TLSA a Micro Cap stock.
TIZIANA LIFE SCIENCES LTD (TLSA) currently has 9 employees.
TIZIANA LIFE SCIENCES LTD (TLSA) has a support level at 1.46 and a resistance level at 1.69. Check the full technical report for a detailed analysis of TLSA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TLSA does not pay a dividend.
TIZIANA LIFE SCIENCES LTD (TLSA) will report earnings on 2025-06-23, after the market close.
TIZIANA LIFE SCIENCES LTD (TLSA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.11).
The outstanding short interest for TIZIANA LIFE SCIENCES LTD (TLSA) is 0.99% of its float. Check the ownership tab for more information on the TLSA short interest.
ChartMill assigns a technical rating of 10 / 10 to TLSA. When comparing the yearly performance of all stocks, TLSA is one of the better performing stocks in the market, outperforming 96.25% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to TLSA. The financial health of TLSA is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months TLSA reported a non-GAAP Earnings per Share(EPS) of -0.11. The EPS increased by 36.02% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -105.13% | ||
ROE | -301.4% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to TLSA. The Buy consensus is the average rating of analysts ratings from 7 analysts.